References
- Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010–18
- Yaegashi Y, Onoda T, Tanno K, Kuribayashi T, Sakata K, Orimo H. Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol 2008;23:219–25
- Clinical practice guidelines for the diagnosis and treatment of primary osteoporosis. Chinese Society of Bone and Mineral Research, CSOBMR. Chin J Osteoporosis Bone Miner Res 2011;4:2–17
- Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;116:2465–74
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
- Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529–39
- Meyer HE, Lofthus CM, Søgaard AJ, Falch JA. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Osteoporos Int 2009;20:827–30
- Nam HS, Kweon SS, Choi JS, et al. Racial/ethnic differences in bone mineral density among older women. J Bone Miner Metab 2013;31:190–8
- Cheng XG, Yang DZ, Zhou Q, et al. Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. J Clin Densitom 2007;10:276–84
- Sang GW, Liu XH, Shao QX, Ge JL, Mao SM, Lu FY. [Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. Zhongguo Yao Li Xue Bao 1991;12:184–7
- Massart F, Brandi ML. Bone mass pharmacogenetics and ethnic health implications. Clin Cases Miner Bone Metab 2007;4:131–8
- Massart F. Human races and pharmacogenomics of effective bone treatments. Gynecol Endocrinol 2005;20:36–44
- Lazovic G, Radivojevic U, Milosevic V, Lazovic A, Jeremic K, Glisic A. Tibolone and osteoporosis. Arch Gynecol Obstet 2007;276:577–81
- Tuppurainen M, Härmä K, Komulainen M, et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. Maturitas 2010;66:423–30
- Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 2002;5:390–8
- Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 2014;142:155–70
- Clinical guideline of menopause management and hormone replacement therapy (2012 edition). Chin J Obstet Gynecol 2013;48:795–9